Progesterone (P4) is essential for female fertility. The objective of this study was to evaluate the functional requirement of the nonclassical P4 receptor (PGR), PGR membrane component 1, in regulating female fertility. To achieve this goal, the 
.0002) in the number of pups/litter. Neither the capacity to ovulate in response to gonadotropin treatment nor the expression of PGR and the estrogen receptor was altered in the uteri of Pgrmc1
mice compared with Pgrmc1 fl/fl control mice. Although conditional ablation of Pgrmc1 from mesenchymal tissue using Amhr2 cre/ϩ mice did not reduce the number of pups/litter, the total number of litters born in the 6-month breeding trial was significantly decreased (P ϭ .041). In addition to subfertility, conditional ablation of Pgrmc1 using either Amhr2 cre/ϩ or Pgr cre/ϩ mice resulted in the development of endometrial cysts starting around 4 months of age. Interestingly, pregnancy attenuated the formation of these uterine cysts. These new findings demonstrate that PGR membrane component 1 plays an important role in female fertility and uterine tissue homeostasis.
(Endocrinology 157: 3309 -3319, 2016) P rogesterone (P4) is an essential hormone that exerts its actions at all levels of the reproductive axis. Faulty P4 signaling is linked to a number of reproductive diseases including endometriosis, infertility, breast and endometrial cancer, irregular menstrual bleeding, adenomyosis, miscarriage, preterm labor, and leiomyoma (1) (2) (3) (4) (5) (6) (7) . In the uterus, P4 attenuates estradiol (E2)-induced epithelial cell proliferation and facilitates cellular differentiation in preparation for the establishment and maintenance of pregnancy (8) . P4 is essential for endometrial stromal cell proliferation and decidualization in invasively implanting species (9, 10) . In the rodent ovary, P4 plays an essential role in the ovulatory process and these actions are mediated by PGR. P4 also acts directly on granulosa cells to inhibit mitosis and apoptosis despite lacking expression of the classical nuclear P4 receptor (PGR) (11) . P4 also promotes the viability and steroidogenic potential of luteal cells and stimulates both its own secretion and cholesterol biosynthesis (12, 13) . Many of the actions of P4 within the ovary and uterus are mediated by the PGR. However, not all of these actions can be explained by activation of PGR.
If not PGR, then what other receptors could mediate the actions of P4 in the uterus and ovary? The rapid, nonclassical actions of P4 are well known to regulate ion flux in neurons (14) , vascular smooth muscle (15) , and epithelial cells (16) , as well as in meiotic maturation (17) , the acrosome reaction (18, 19) and sexual behavior (20) . Further, P4 elicits modulatory actions in immune cells that are completely devoid of PGR expression (21) . Although nonclassical P4 signaling is often synonymously referred to as "nongenomic," several studies have now shown that P4 regulates transcriptional activity in cells and tissues that lack expression of PGR (22, 23) , so perhaps the "nonclassical" designation is more appropriate.
Recent in vitro studies revealed that some actions of P4 are mediated by PGR membrane component 1 (PGRMC1). Spectroscopic and mutagenesis studies show human PGRMC1 binds P4 with high affinity (24) . Moreover, the presence of PGRMC1 in membrane fractions correlates with an increase in high-affinity P4 binding (25, 26) . PGRMC1 mediates the antiapoptotic and antimitotic actions of P4 in granulosa cells (27) , as well as in ovarian and endometrial cancer cell lines (28, 29) . PGRMC1 is proposed as a nonclassical PGR that, in general terms, localizes at the subcellular level to the endoplasmic reticulum, nucleus, and plasma membrane in most cells that express the protein (30, 31) . PGRMC1 is most abundantly expressed in the endometrium during the proliferative phase of the macaque and human menstrual cycles (32) (33) (34) and therefore may have a role in the management of endometrial epithelial cell cycle progression. In the macaque, the cellular distribution of PGRMC1 changed in response to steroid hormone supplementation in an artificial model of the menstrual cycle (32) . The cellular distribution of PGRMC1 was most abundant during the proliferative phase in both epithelial and stromal cells. By the late secretory phase, PGRMC1 expression was restricted to most stromal cells of the basalis, and scattered stromal cells within the functionalis. Individual cells of the luminal epithelium expressed PGRMC1, particularly at the apical surface. In the mouse, PGRMC1 is weakly expressed in both the stromal and epithelial compartments during estrus, becomes robustly expressed in both tissue types during metestrus, and then declines again during diestrus (35) . PGRMC1 expression is also highly regulated at the maternal:fetal interface in human and rodents, as well as during the estrous/menstrual cycle in a number of species (35, 36) . The expression pattern for PGRMC1 is quite distinct from PGR. For instance, during the periimplantation period on day 4 of pregnancy, whereas PGR expression is lost in the luminal epithelium, PGRMC1 expression is retained in this tissue, suggesting a distinct uterine role for this P4 mediator (35) . Finally, PGRMC1 expression is reduced in fetal membranes among women with preterm premature rupture of the membranes (37) , as well as in ectopic and eutopic endometrial stroma of women with endometriosis (38) . PGRMC1 was recently identified as being differentially regulated in receptive vs nonreceptive endometria of women undergoing hormone therapy for in vitro fertilization (39) . With this collective information from women and model organisms, it is hypothesized that PGRMC1 plays an important role in maintaining normal female reproductive functions. This hypothesis was tested through the development and use of a floxed Pgrmc1 allele (Pgrmc1 fl/fl ) and evaluation of conditional Pgrmc1 ablation in the female reproductive tract.
Materials and Methods

Floxing the Pgrmc1 allele and genotyping
All animal procedures were approved by Institutional Animal Care and Use Committees at Washington State University or the University of Connecticut Health Center. A Pgrmc1 targeting vector was prepared by recombineering according to Lee et al (40) . Briefly, an 11-kb section of the Pgrmc1 genomic sequence containing all 3 exons and 0.5 kb of the 5Ј-upstream and 3Ј-downstream sequences was retrieved from the BAC, RP23-75F15, pPL253 by gap repair. A 5Ј loxP site was inserted into intron 1 approximately 500 bp upstream of exon 2 followed by insertion of Frt-PGFneo-Frt-LoxP into intron 2 approximately 600 bp downstream of exon 2. The vector, which contained approximately 6 and 3.8 kb of the 5Ј and 3Ј arms, respectively, was linearized by NotI and electroporated into mouse ES cells derived from an F1(129Sv/C57BL6j) blastocyst. The cells were then cultured in the presence of 150 g/ml of G418 and 2M ganciclovir. Drug resistant colonies were selected and screened by nested long range PCR using primers corresponding to sequences outside the arms and specific to the 5Ј and 3Ј loxP sites to identify targeted ES clones. Targeted ES cells were used to generate chimeric animals by aggregation with CD1 morula. and Amhr2 cre/ϩ colonies was assessed by mating 6-week-old female mice with male mice of proven breeding capacity in 6-month breeding trials. The number of litters and number of pups/litter were determined through the duration of the trials. Female reproductive tracts were collected from mice at the end of the breeding trials, as well as from young and aged nulliparous female mice for histological analyses.
Animals and treatments
Superovulation was used to assess ovarian capacity to ovulate. (Pgr-cre) mice under synchronized conditions, sexually mature female mice were first ovariectomized. The mice were then given daily sc injections of E2 (100 ng) diluted in sesame oil for 3 consecutive days. After 2 days, mice were treated with E2 (100 ng) for 2 days as before and uteri were collected 18 hours after the last injection. Uterine tissues were collected and partitioned for RNA isolation and fixation in 4% paraformaldehyde in preparation for paraffin embedding and RT-PCR as described below.
Western blotting validation of uterine Pgrmc1 ablation
To confirm that PGRMC1 was conditionally ablated from uterine tissues, protein was isolated from uterine and liver tissue samples from sexually mature female Pgrmc1 fl/fl and Pgrmc1
(Pgr-cre) mice. Protein lysates were generated as described elsewhere (43) . Briefly, 25 g of total protein from each sample were separated electrophoretically using the NuPage system (Invitrogen) and transferred (30 V, 1 h) onto polyvinylidene difluoride membranes. Nonspecific binding was blocked with 5% BSA in 0.1% Tween 20 in PBS (PBST) buffer for 1 hour at room temperature. Primary antibody (anti-PGRMC1, 1:1000 dilution; Sigma Chemical Co) was diluted in PBST with 5% BSA and applied to membranes for overnight incubation at 4°C. Membranes were washed (3 ϫ 60 min) in PBST and incubated with secondary antibody (Cell Signaling Technology) for 1 hour at room temperature. After a second series of washes, bound antibodies were detected with enhanced chemiluminescent reagents using the manufacturer's recommendations (Thermo Scientific). Chemiluminescent signals were captured and quantified using the Bio-Rad ChemiDoc MP Imaging System.
Histology and immunohistochemistry
Paraffin-embedded uterine and ovarian tissues were sectioned (5 m), deparaffinized, and rehydrated in graded ethanol. For general histology, slides were stained with hematoxylin and eosin (Scytek Laboratories, Inc). For sections used in immunohistochemical studies, peroxidase quenching (10 min in 10% hydrogen peroxide) was completed, and antigen retrieval was performed by boiling sections in a 0.1M sodium citrate buffer for 10 minutes. After boiling and reaching room temperature, sections were blocked (0.1% BSA, 0.1% normal goat serum, and 1% Triton X-100 in PBS) for 1 hour at room temperature. Sections were then incubated overnight at 4°C with the primary antibody diluted into blocking solution. After incubation, slides were washed in PBS 3 times 10 minutes each and then incubated with biotinylated secondary antibody (1:500 goat antirabbit IgG-B; Santa Cruz Biotechnology, Inc) for 45 minutes. Slides were washed as before and then incubated with horseradish peroxidase-conjugated streptavidin (Vector Laboratories). Washes were performed and the sections were exposed to 3,3Ј-diaminobenzidine (BD Biosciences) followed by a 5-minute inactivation in PBS. Sections were then counterstained with hematoxylin. Sections on slides were sequentially rehydrated and mounted after air drying. In all experiments, specificity of the primary antibody was confirmed by omission of this antibody in parallel slides. 
RNA isolation and RT-PCR
Data analyses
Assignment to all treatment groups was made randomly. Data are presented as the mean Ϯ SEM for n ϭ 3-8 for each experiment where individual animals represent a single experimental replicate. Differences between treatment groups were assessed by Student's t test where the mean values of only 2 groups were compared. A two-way ANOVA was used to identify treatment effects in the breeding trials followed by a Bonferroni post hoc test. P Յ .05 was considered significant. All data were analyzed using GraphPad 5.0 software.
Results
Conditional ablation of the Pgrmc1 allele
The X-linked Pgrmc1 allele was conditionally ablated by crossing Pgrmc1 fl/fl mice with either Amhr2 cre/ϩ or Pgr cre/ϩ mice. An illustration of the floxing strategy, as well as tissues expressing cre recombinase in each driver is shown in Figure 1A . After crosses between cre driver mice and Pgrmc1 fl/fl mice, DNA isolated from tail snip samples 
doi: 10.1210/en.2016-1081 press.endocrine.org/journal/endo 3311 was used to confirm mouse genotype. The wild type allele was recognized by PCR as a 459-bp cDNA, and the mutant allele was 532 bp in size ( Figure 1B ). The detection of both cDNAs identified heterozygous animals. The presence of the cre recombinase transgene was determined by PCR as described elsewhere (41, 42) . Western blot analysis confirmed that the approximately 28-kDa PGRMC1 protein was conditionally ablated from the uteri of Pgrmc1 d/d mice using the Pgr cre/ϩ mice but not from the liver ( Figure 1C) . A lower molecular weight immunoreactive band was detected at reduced levels in Pgrmc1
uterine tissue samples, which presumably represents a truncated form of PGRMC1 that lacks exon 2.
Conditional ablation of Pgrmc1 impairs fertility
The number of pups/litter was determined in 6-month breeding trials to evaluate fecundity of Pgrmc1 (Figure 2A and Table 3 Figure  3A) . This observation at the mRNA level extended to the protein level where ESR1 and PGR were found to be temporospatially expressed at comparable levels between Pgrmc1 fl/fl and Pgrmc1 d/d mice ( Figure 3B ). Specifically, ESR1 was expressed in most cells of the stromal and epithelial compartments, whereas PGR was restricted in its expression to the stromal compartment. (Figure 4) . A more profound phenotype was observed in PGRMC1-deficient mice using Pgr cre/ϩ which resulted in a 2-to 4-fold increase in uterine volume due to formation of larger cystic glands. Ablation of Pgrmc1 using Amhr2 cre/ϩ mice also resulted in cyst formation. Interestingly, heterozygous female mice harboring one intact Pgrmc1 allele also displayed cysts. Development of the cystic phenotype was absent from young nulliparous animals and was dependent on age ( Figure 5 ). Of note, 
Development of endometrial cysts in
Discussion
An unequivocal role for PGR in mediating the actions of P4 has been established through functional studies in Pgr null female mice and through pharmacological studies where PGR antagonists such as RU486 have been employed. The Pgr null mutation results in complete infertility and development of hyperplasia (44) . However, PGR is not the sole receptor mechanism for mediating P4 actions, because cells that lack expression of PGR still respond to P4 and synthetic nonmetabolizable progestins such as R5020 (11, 22, 25, 27, 36, (45) (46) (47) . To date, 2 families of nonclassical PGRs have been identified including the Progestin and AdipoQ receptor (PAQR) and PGRMC families (30, 44, 48 -50) . Members of the PAQR family belong to the G protein-coupled receptor superfamily and purported P4 mediators include Paqr5, Paqr7, and Paqr8, all of which have been cloned and partially characterized in mammals (51) . Although the activity of these receptors has been established in in vitro studies (52) , others have challenged the validity of the PAQRs as bona fide progestin receptors in vivo (53, 54) . The second family of nonclassical progestin receptors is the PGRMC family, which include PGRMC1, PGRMC2, neudecin, and neuferricin. PGRMC1 and PGRMC2 were originally cloned as heme-1 domain proteins referred to as HPR6.6 and Dg6, respectively (55) (56) (57) . The actions of PGRMC1 and PGRMC2 have been demonstrated in a number of in vitro culture systems. However, in vivo functional studies have not been completed for members of the PGRMC family with regard to fertility, although PGRMC1 was recently shown to be necessary for altering cyclic regulation of sensory perception by P4 (58) . Interestingly, the actions of members of the PGRMC and PAQR families may be linked, as a physical interaction between PGRMC1 and PAQR7 in cultured cells has been demonstrated (59, 60) . The present study demonstrates for the first time that Pgrmc1 is necessary for reproductive function in the female where conditional ablation of this gene results in impaired fertility and contributes to the development of endometrial cysts consistent with premature aging. The Pgrmc1 floxed mouse was generated by inserting loxP sites on either side of exon 2. Exon 2 is significant be- 
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cause it contains the cytochrome b5-like heme/steroidbinding domain, as well as several predicted phosphorylation sites, kinase binding sites, and Src homology 2 and Src homology 3 targeting domains. This region of PGRMC1 has been shown to be essential for binding P4 and for mediating the antiapoptotic actions of P4 (61) . Using Pgr cre mice to ablate Pgrmc1, the present studies reveal a greater than 40% reduction in the number of pups/litter throughout the duration of the 6-month breeding trial. The observed reduction in the number of pups/litter is evident from the first pregnancy at 6 weeks of age onward. In these mice, cre recombinase is expressed in all cells of the female reproductive tract, granulosa cells of periovulatory follicles, mammary glands, gonadotrophs, and select hypothalamic neurons. Although more extensive analyses are required, the subfertility phenotype observed when using the Pgr cre driver mouse likely does not stem from faulty hypothalamic or pituitary function, which would result in abnormal estrous cycles, because there was no difference in the number of days between litters when comparing Pgrmc1 fl/fl and Pgrmc1 d/d mice. Similarly, the subfertility phenotype does not stem from luteal insufficiency or failure of the ovary to respond to gonadotropins given that superovulation re- Analysis of ESR1 and PGR suggest that uteri from Pgrmc1 d/d mice retain the capacity to respond to E2 and P4 through classical routes, because the expression of these classical steroid receptors was similar to that observed in Pgrmc1 fl/fl mice. This observation suggests that ablating Pgrmc1 from uterine cells dramatically alters uterine responses to ovarian steroids without altering the expression of either of the classical ESR1 or PGR. The mechanism by which conditional ablation of Pgrmc1 from uterine cells alters uterine function and impairs fertility remains to be determined. celerates the aging process of this tissue. Finally, the age onset development of cysts likely did not contribute to the subfertility phenotype given that the reduction in the number of pups/litter was observed from the time of sexual maturity at 6 weeks of age, and this remained consistent through the duration of the breeding trial even after cyst formation. It therefore seems that parity realigned the Pgrmc1 d/d endometrial histoarchitecture or slowed the aging process so that the functional capacity of the uterus was not diminished below the observed 4.6 pups/litter. This is supported by the dramatic decline in cyst formation in endometrial tissue of aged multiparous Pgrmc1 d/d mice as shown in Figure 5 . The cysts that form are not mitotic and therefore are more consistent with inclusion cysts. Pregnancy likely minimizes cyst formation by decreasing the total number of estrous cycles throughout reproductive life and by eliminating disrupted endometrial tissue that may accumulated during estrous cyclicity.
The exact function(s) of PGRMC1 in the gravid uterus and its regulation by P4 remain to be determined. However, several recent reports from in vitro studies provide a framework with which to begin to evaluate how PGRMC1 functions in the uterus. In vitro studies using A549 lung cancer cells demonstrate that PGRMC1 forms a physical interaction with the epidermal growth factor receptor (EGFR) and this interaction is necessary for EGFR translocation from cytoplasmic vesicles to the cell surface for interactions with its cognate ligand. Depletion of PGRMC1 in these cells also made them increasingly sensitivity to the EGFR inhibitor, erlotinib (62, 63) . If a similar EGFR vesicular transport function for PGRMC1 exists in the endometrial stromal compartment, it is possible that conditional ablation of Pgrmc1 results in a diminished presence of EGFR at the cell surface. Such a scenario could account for the postimplantation phenotype in the Pgrmc1 d/d mouse given that EGFR was recently shown to be essential for decidualization and normal fertility (64) . We previously reported on the expression of PGRMC1 in gravid human and murine uteri (35) . Importantly, during the periimplantation period, PGRMC1 is expressed in the luminal epithelium surrounding the implanting embryo, as well as in subluminal stromal cells undergoing the decidualization program. This is in contrast to expression of the classical PGR, which is known to be absent from the luminal epithelium at the time of embryo implantation in all mammalian species studies to date regardless of the type of implantation. The interesting nuclear staining of PGRMC1 in decidualizing stromal cells during early gestation suggests a function for this protein in the decidualization process.
Alternative actions for PGRMC1 include its roles in regulating cell cycle progression and apoptosis. In spontaneously immortalized rat granulosa cells and human granulosa/lutein cells PGRMC1 is necessary for mediating the antimitotic actions of P4 in these cells (60, 65) . During early pregnancy, stromal cells undergo several rounds of proliferation before terminal differentiation into decidual cells. This proliferative event is stimulated by P4, as is the terminal differentiation of these cells. Previous expression analysis of PGRMC1 at the maternal-embryo interface in mice revealed that PGRMC1 is abundantly expressed in the nucleus of cells that are transitioning out of the cell cycle and toward a differentiated state (35) . It will be interesting to determine whether PGRMC1 mediates the antimitotic actions of P4 in this context. Likewise, PGRMC1 and PGRMC2 have an antiapoptotic function in spontaneously immortalized rat granulosa cells (65, 66) . Similarly, it has now been established in endometrial, ovarian, and breast cancer cell lines, all of which are deficient in PGR expression, that PGRMC1 mediates the antiapoptotic actions of P4 (28, 29, 67) . Depletion of PGRMC1 from each of these cancer cell lines makes them more sensitive to the killing actions of chemotherapeutic agents such as cisplatin and doxorubicin. One explanation for the postimplantation decidualization defect in Pgrmc1
mice is that the absence of PGRMC1 could make decidual cells more sensitive to apoptotic stimuli. Further evaluation of this concept is needed. 
